Concizumab

Drug Profile

Concizumab

Alternative Names: Anti-TFPI; mAb-2021; NN-7415; NNC-0172-0000-2021; NNC-0172-2021; NNC-172-2021

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Monoclonal antibodies
  • Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Haemophilia

Most Recent Events

  • 03 Dec 2016 Preclinical results from studies in Haemophilia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology
  • 01 Oct 2016 Novo Nordisk completes the Explorer3 trial in Haemophilia in USA, Australia, Austria, Croatia, France, Germany, Israel, Malaysia, Spain, Thailand, the Netherlands, Poland, Turkey, Ukraine and United Kingdom (NCT02490787)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Haemophilia in Austria (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top